TIM-4 Identifies IFN-{gamma}-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection [TRANSPLANTATION]

B cells give rise to polarized subsets, including B effector 1 (Be1) cells and regulatory B cells, which can promote or inhibit immune responses through expression of IFN- and IL-10, respectively. Such subsets likely explain why B cell depletion can either ameliorate or exacerbate inflammatory diseases; however, these cells remain poorly understood because of the absence of specific markers. Although T cell Ig and mucin domain-containing molecule (TIM)-1 broadly identifies IL-10⁺ regulatory B cells, no similar markers for Be1 cells have been described. We now show that TIM-4 is expressed by a subset of B cells distinct from those expressing TIM-1. Although TIM-1⁺ B cells are enriched for IL-10, TIM-4⁺ B cells are enriched for IFN-. TIM-1⁺ B cells enhanced the growth of B16-F10 melanoma. In contrast, TIM-4⁺ B cells decreased B16-F10 metastasis and s.c. tumor growth, and this was IFN- dependent. TIM-1⁺ B cells prolonged islet allograft survival in B-deficient mice, whereas TIM-4⁺ B cells accelerated rejection in an IFN-–dependent manner. Moreover, TIM-4⁺ B cells promoted proinflammatory Th differentiation in vivo, increasing IFN- while decreasing IL-4, IL-10, and Foxp3 expression by CD4⁺ T cells—effects that are opposite from those of TIM-1⁺ B cells. Importantly, a monoclonal anti–TIM-4 Ab promoted allograft tolerance, and this was dependent on B cell expression of TIM-4. Anti–TIM-4 downregulated T-bet and IFN- expression by TIM-4⁺ B cells and indirectly increased IL-10 expression by TIM-1⁺ B cells. Thus, TIM-4⁺ B cells are enriched for IFN-–producing proinflammatory Be1 cells that enhance immune responsiveness and can be specifically targeted with anti–TIM-4.

http://ift.tt/2xbBYZ1